January 19, 2022 -- Ori Biotech has obtained over $100 million in an oversubscribed series B funding round. Ori said it will use the funds to further expand key personnel across all functions to prepare for the launch of its cell and gene therapy (CGT) manufacturing platform.
The company is also launching its Lightspeed Early Access program in which select partners can gain prelaunch access to the Ori platform, a proprietary, full-stack manufacturing system that closes, automates, digitizes, and standardizes CGT manufacturing.
The investment round was led by Novalis LifeSciences, with Puhua Capital and Chimera Abu Dhabi as new investors. Existing investors from Ori's $30 million series A round in 2020 included Amadeus Capital Partners, Delin Ventures, Northpond Ventures, and Octopus Ventures.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
